A Study to Assess Injection Comfort of Two Formulations of ATX-101

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the safety and injection comfort of ATX-101-BA versus ATX-101-BA-free immediately following injection and at regular intervals up to 24-hours post-injection following subcutaneous administration into the submental area.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101

NCT01462786

Healthy

COMPLETED PHASE1

Open-Label Pharmacokinetic Study of Final Formulations of ATX-101

NCT01632917

Healthy

COMPLETED PHASE1

Dose-Escalation Safety and Pharmacokinetic Study of ATX-101

NCT00618709

Healthy

COMPLETED PHASE1

Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 Into Abdominal Fat Tissue

NCT01319916

Healthy

COMPLETED PHASE1

Pharmacokinetic Study of ABT-126 in Healthy Volunteers

NCT00959634

Healthy Volunteers

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1A

Left side injected first:

Left submental - ATX-101-BA Right submental - ATX-101-BA-free

Group Type EXPERIMENTAL

ATX-101-BA-free

Intervention Type DRUG

ATX-101-BA-free

ATX-101-BA

Intervention Type DRUG

ATX-101-BA

Group 1B

Right side injected first:

Left submental - ATX-101-BA Right submental - ATX-101-BA-free

Group Type EXPERIMENTAL

ATX-101-BA-free

Intervention Type DRUG

ATX-101-BA-free

ATX-101-BA

Intervention Type DRUG

ATX-101-BA

Group 2A

Left side injected first:

Left submental - ATX-101-BA-free Right submental - ATX-101-BA

Group Type EXPERIMENTAL

ATX-101-BA-free

Intervention Type DRUG

ATX-101-BA-free

ATX-101-BA

Intervention Type DRUG

ATX-101-BA

Group 2B

Right side injected first:

Left submental - ATX-101-BA-free Right submental - ATX-101-BA

Group Type EXPERIMENTAL

ATX-101-BA-free

Intervention Type DRUG

ATX-101-BA-free

ATX-101-BA

Intervention Type DRUG

ATX-101-BA

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ATX-101-BA-free

Intervention Type DRUG

ATX-101-BA

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Presence of submental fat graded by the investigator as 2, 3, or 4 using the CR-SMFRS (Appendix B).
2. Sufficient and symmetrical submental fat such that the protocol-specified number of injections can be safely administered on both the right and left side.
3. No difference in perception or sensitivity (pain or otherwise) between left and right sides of the submental area.
4. Abstinence from alcohol for at least 6 hours prior to both the Baseline and 24-hour visits.
5. Males or nonpregnant, nonlactating females who are aged 18 to 65 years, inclusive, on Baseline date.
6. Females of child-bearing potential must have a negative urine human chorionic gonadotropin (hCG) test result from a sample obtained during the screening period. Females of childbearing potential must agree to practice adequate contraception, in the judgment of the investigator, during the course of the trial (including post-screening).
7. The subject is expected to comply with and understand the visit schedule and all of the protocol-specified tests and procedures.
8. The subject is medically able to undergo the administration of study material as determined by clinical and laboratory evaluations obtained within 14 days before dosing with study material for which the investigator identifies no clinically significant abnormality.
9. Signed informed consent obtained before any study-specific procedure is conducted.

Exclusion Criteria

1. History of any intervention (e.g., liposuction) or trauma associated with the chin or neck areas, which in the judgment of the investigator, may affect subject safety or other evaluations of treatment.
2. Evidence of any cause of enlargement in the submental area (e.g., thyroid enlargement, cervical adenopathy) other than localized submental fat.
3. Any medical condition (e.g., respiratory, cardiovascular, hepatic, neurological disease, uncontrolled hypertension, thyroid dysfunction), that would interfere with the assessment of safety in this trial or would compromise the ability of the subject to undergo study procedures or to give informed consent.
4. Any cognitive impairment that, in the Investigator's opinion, would preclude study participation or compliance with protocol-specified procedures.
5. Treatment with analgesics or other agents that could affect the pain response, including but not limited to acetaminophen or ibuprofen taken within 1 day prior to Baseline; additionally, narcotic analgesics, tranquilizers, hypnotics, sedatives, or opiates within 7 days prior to Baseline.
6. Treatment of the chin or SMF with injectable steroids within 90 days prior to Baseline.
7. Participation in a pain study within 6 months prior to Baseline.
8. History of chronic pain and/or a history of chronic analgesic or tranquilizer use within 90 days prior to Baseline.
9. Any anticipated need for agents with anticoagulative effects (e.g., aspirin, ibuprofen, warfarin, heparin) during the course of the trial.
10. Treatment with oral anticoagulants (e.g., aspirin, warfarin) within 10 days prior to Baseline.
11. Treatment with topical agents to the submental or neck area, including but not limited to creams or ointments used to treat dermatologic conditions (e.g., steroids, capsaicin, retinoids, fluorouracil) within 7 days prior to Baseline.
12. Treatment with radio frequency, laser procedures, chemical peel, or dermal fillers in the neck or chin area within 12 months before dosing or botulinum toxin injections within 6 months prior to Baseline.
13. Previous enrollment into this trial or treatment with ATX-101 or agents containing deoxycholate.
14. Treatment with an investigational agent within 28 days prior to Baseline.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes